• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Guest Article – Leprosy Drug Clofazimine Set For New Roles

Guest Article – Leprosy Drug Clofazimine Set For New Roles

0
By Biotech Express on August 17, 2021 Articles, Articles- Guestorials, SARS- CoV2 & COVID-19 Updates

Nabanita Das, PhD
Email: dasnabanita123@gmail.com
SERB-National Postdoctoral fellow, CSIR-Central Drug Research Institute, Sector-10, Jankipuram extension, Sitapur Road, Lucknow-22603, Uttar Pradesh. India.

Abstract
Development of a brand new drug takes enormous toll on time, money and effort, due to bottlenecks in therapeutic development. Strategically repurposing drugs for other uses can save time and money, as their pharmacology, formulation and potential toxicity are already known. The preclinical phase includes a demonstration of its efficacy in invitro or in vivo model system and then filing the experimental new drug application with the U.S. Food and Drug Administration (FDA), it typically enters into clinical phase II trials. The cost of launching a repurposed drug is approximately 85% less than for a de novo drug. Besides repurposed drugs, repositioned and rescued drugs generate 25% of annual revenues for the pharmaceutical industry as per the estimate. There are multiple illustrations of drug repurposing to date, the pioneer was the repurposing of thalidomide, initially a sedative and anti-leprosy, later approved for the treatment of multiple myeloma by USFDA in 2012.

Clofazimine (CFZ), primarily known for its anti-leprosy activity is shown to be effective against primary interventions for multidrug-resistant tuberculosis, chronic myelogenous leukemia (CML), and more recently SARS-CoV-2. CFZ was discovered during 1950s at Trinity College, Dublin, was approved for use in the United States in 1986, presently it is in WHO list of essential medicines.

The efficacy of CFZ against Mycobacterium Avium Complex (MAC) was demonstrated by Jarand et. al. from University of Calgary, Canada in 2016. CFZ administered in combination with macrolide and ethambutol was shown to be highly effective in treatment of MAC. The work was recognized and published in the renowned journal CHEST.

The research group at CSIR-Central Drug Research Institute, Lucknow in collaboration with Zydus Research Centre, Ahmedabad and King Georges Medical University, Lucknow has demonstrated that CFZ can defeat leukemic stem cells (LSCs) and resists relapse in CML patients.

CML, a type of cancer affecting blood and bone marrow developed due to chromosomal aberrations is one of most recurrent adult leukemia in Indian population, which accounts for 30%-60% of all leukemia. The management of CML was revolutionized by the targeted treatment with imatinib that has become the standard treatment of choice. The second-generation of medicine includes nilotinib, dasatinib administered to patients resistant or intolerant to first-generation of drugs. However, although effective, second-line therapy comes at a significant expense. It has been estimated that the cost can measure up to $800000 per quality-adjusted life-year compared to generic imatinib. Moreover, a considerable number of patients suffer from relapse and progression when the first/second-line therapy stops due to the activity of leukemic stem cells (LSCs).

The breakthrough research from the group shows CFZ is particularly effective in imatinib-resistant patients and terminates LSCs including notorious quiescent stem cells derived from CML patients without causing harm to hematopoietic cells derived from healthy individuals. The drug could successfully over empower cellular leukemic/oncogenic factors often associated with multidrug-resistant patients. Interestingly CFZ when administered in combination with imatinib at a significantly low physiological dose known so far, proved exceptionally effective in comparison to monotherapy. The outcome of the study was published in a reputed journal, HAEMATOLOGICA. Leukemic stem cells possess immense hindrance to the existing drugs, as they are incapable of targeting quiescent stem cells. The identified drug from the study could overcome this hindrance and can be proposed for its further clinical evaluation.

The future of this comprehensive study depends directly on clinical evaluation in humans because preclinical validations, pharmacokinetics and toxicity studies have already been performed in detail. Successful execution of clinical trials will render healthcare much more affordable for CML patients of Indian origin. The research team with their disease-centric viewpoint screened over most possible repurposing candidates for the treatment of chronic myeloid leukemia and has come across CFZ. Again, they have explored the use of novel combination therapies, where the repurposed drug increases the efficiency of imatinib, a well-known treatment and could dramatic improvements in outcomes. This research promises that in the future treatment of CML who are resistant to existing drugs or relapse patients will benefit from it as the cure will become within reach in economically backward parts of India. Clinicians can bank on CFZ repurposing for the treatment of chronic myeloid leukemia.

Most recently in 2020, researchers from Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong demonstrated that CFZ was capable of inhibiting SARS-CoV-2 multiplication in hamsters. Their research published in the highly reputed journal NATURE reports CFZ to be effective against several coronaviruses in including the novel coronavirus. Novel emerging infectious diseases like the present COVID-19 possess extreme challenges to the healthcare systems. This creates an urgent need for effective pharmacological treatments. The demand can only be fulfilled by repurposing drugs due to the lack of available time for new drug formulation. The antiviral synergism between clofazimine and remdesivir, the first ever-pharmacological approach towards prevention of Covid-19 has a promising future. Repurposing clofazimine thus brings a ray of hope for combating the prevalent pandemic situation.

References:
1. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Alan Talevi and Carolina L Bellera. Expert Opin Drug Discov. 2020 Apr;15(4):397-401.
2. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. Julie Jarand, J Paul Davis, Robert L Cowie, Stephen K Field, Dina A Fisher. Chest. 2016 May;149(5):1285-93.
3. Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells. Sabyasachi Sanyal et. al. Haematologica 2020 Apr;105(4):971-986.
4. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Kwok-Yung Yuen et. al. Nature. 2021 May;593(7859):418-423.

 

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.